Abstract:AL amyloid cardiomyopathy is characterized by the deposition of amyloid fibers from monoclonal immunoglobulin light chain proteins (AL-LC) in the heart. We and others have shown that AL-LC directly results in cardiac toxicity; however, the mechanisms underlying this toxicity remain to be determined. Morphological examinations of hearts from patients with AL amyloid cardiomyopathy reveal increased double membrane autophagosome-like structures and mitochondrial deformation. Using isolated adult rat cardiomyocytes, we therefore examined whether dysregulated autophagy mediates the development of AL-LC induced cardiac toxicity. Methods and Results: Autophagy is a dynamic process and autophagic flux is, hence, determined by measurement of LC3-II protein expression in the absence and presence of lysosome inhibitors (E64d and pepstatin A). The autophagic substrate, polyubiquitin-binding protein (p62), was also examined via immunoblotting. We found that LC3-II expression increased in the absence but decreased in the presence of lysosome inhibitors in cardiomyocytes exposed to AL-LC relative to vehicle control. Moreover, p62 expression was increased in AL-LC treated cardiomyocytes, suggesting that AL-LC resulted in impaired clearance of autophagosomes in cardiomyocytes. To define the causal relationship between dysregulated autophagic clearance and AL-LC induced cardiac toxicity, we determined the functional consequences of autophagic inhibition by treatment with 3MA (3-Methyladenine, PI3K inhibitor), or autophagic activation by treatment with rapamycin (mTOR inhibitor). Inhibition of autophagy led to worsen of AL-LC induced cardiac toxicity whereas activation of autophagy protected cardiomyocytes against AL-LC induced cardiac toxicity, as measured by ROS production and cell death. Conclusion: Our data demonstrate that AL-LC directly results in impaired autophagic clearance in cardiomyocytes, contributing to the development of amyloid cardiac toxicity and cardiomyopathy. Therapies aimed at modulation of cellular autophagy may provide new treatment approaches for patients with AL amyloid cardiomyopathy.

Plasmalogens Alter the Aggregation Rate of Transthyretin and Lower Toxicity of Transthyretin Fibrils

Cholesterol and Sphingomyelin Uniquely Alter the Rate of Transthyretin Aggregation and Decrease the Toxicity of Amyloid Fibrils

Abstract 18695: Role of Autophagy in Amyloidogenic Light Chain Induced Cardiac Toxicity

Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression

Secondary structure and toxicity of transthyretin fibrils can be altered by unsaturated fatty acids

Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition

A molecular basis for tetramer destabilization and aggregation of transthyretin Ala97Ser

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)

Aggregation of Transthyretin by Fluid Agitation

Structure-based probe reveals the presence of large transthyretin aggregates in plasma of ATTR amyloidosis patients

Human in vitro disease modeling of ATTR cardiac amyloidosis

The influence of Zwitterionic and anionic phospholipids on protein aggregation

Differential Modification of Cys10 Alters Transthyretin's Effect on Beta-Amyloid Aggregation and Toxicity

A FTIR microspectroscopy study of the structural and biochemical perturbations induced by natively folded and aggregated transthyretin in HL-1 cardiomyocytes

Phosphorylation of CRYAB Induces a Condensatopathy to Worsen Post-Myocardial Infarction Left Ventricular Remodeling.

Investigating a Novel Neurodegenerative Disease Toxic Mechanism Involving Lipid Binding Specificity of Amyloid Oligomers

Transthyretin mutagenesis: impact on amyloidogenesis and disease

The Physical Driving Forces of Conformational Transition for TTR91-96 with Proline Mutations.

Structural and thermodynamic characterization of a highly amyloidogenic dimer of transthyretin involved in a severe cardiomyopathy

Multi-organ structural homogeneity of amyloid fibrils in ATTRv-T60A amyloidosis patients, revealed by Cryo-EM

Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells